搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Targeted Oncology
9 小时
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...
Targeted Oncology
11 小时
STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment
The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...
Targeted Oncology
9 小时
SunRISe-2 Study of TAR-200 Plus Cetrelimab in MIBC Discontinues
The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...
Targeted Oncology
16 小时
Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...
Targeted Oncology
15 小时
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head and Neck Cancer
The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.
Targeted Oncology
13 小时
VLS-1488 Gains FDA Fast Track Status in Advanced Ovarian Cancer
The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.
Targeted Oncology
1 天
Merchan’s Takeaways From the CLEAR Study in Advanced RCC
Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...
Targeted Oncology
1 天
Machine Learning-Based Tool Aims to Enhance Stereotactic Radiosurgery Outcomes
In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local ...
Targeted Oncology
1 天
Overcoming Atypical EGFR Challenges With a Novel Approach
The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...
Targeted Oncology
1 天
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be ...
Targeted Oncology
1 天
Importance of AEGEAN Approval
Panelists discuss how the importance of AEGEAN approval lies in its potential to enhance patient treatment options, paving ...
Targeted Oncology
1 天
Navigating ICI Plus TKI Combinations for First-Line mRCC: Key Factors in Decision-Making
Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈